Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Plan is in accordance with congressionally mandated NDAA procedures to assess, compare and develop methods for dealing with threats of emerging biotechnology.

Kelley M. Sayler April 6, 2022 Emerging Military Technologies: Background and Issues for Congress Updated April 6, 2022 https://sgp.fas.org/crs/natsec/R46458.pdf

Congress has expressed an interest in conducting oversight of the military applications of emerging biotechnologies. For example, per Section 263 of the FY2020 NDAA (P.L. 116-92), DOD is to conduct “a review of the military understanding and relevancy of applications of emerging biotechnologies to national security requirements of the Department of Defense” and provide recommendations for future legislative and administrative activities.” 132 Section 278 of the FY2021 NDAA (P.L. 116-283) directs DOD to “conduct an assessment and direct comparison of capabilities in emerging biotechnologies for national security purposes ... between the capabilities of the United States and the capabilities of adversaries of the United States.” 133 Finally, Section 1091 of the FY2022 NDAA (P.L. 117-81) establishes the National Security Commission on Emerging Biotechnology, which is to “consider the methods, means, and investments necessary to advance and secure the development of biotechnology, biomanufacturing, and associated technologies by the United States to comprehensively address the national security and defense needs of the United States.” The commission is to deliver its interim findings and recommendations to the congressional defense committees and the President no later than January 26, 2023, and its final report no later than January 26, 2024.134

Sign in to recut, update, or save this card.